Arsphenamine
|
WikiDoc Resources for Arsphenamine |
|
Articles |
|---|
|
Most recent articles on Arsphenamine Most cited articles on Arsphenamine |
|
Media |
|
Powerpoint slides on Arsphenamine |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Arsphenamine at Clinical Trials.gov Clinical Trials on Arsphenamine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Arsphenamine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Arsphenamine Discussion groups on Arsphenamine Patient Handouts on Arsphenamine Directions to Hospitals Treating Arsphenamine Risk calculators and risk factors for Arsphenamine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Arsphenamine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Arsphenamine is a drug that was used to treat syphilis and trypanosomiasis. It was the first modern chemotherapeutic agent.
History
Sahachiro Hata discovered the anti-syphilitic activity of this compound in 1908 in the laboratory of Paul Ehrlich, during a survey of hundreds of newly-synthesized organic arsenical compounds. Ehrlich had theorized that by screening many compounds a drug could be discovered with anti-microbial activity. Ehrlich's team began their search for such a "magic bullet" among chemical derivatives of the dangerously-toxic drug atoxyl. This was the first organized team effort to optimize the biological activity of a lead compound through systematic chemical modifications, the basis for nearly all modern pharmaceutical research.
Arsphenamine was marketed under the trade name Salvarsan in 1910. It was also called 606,[1] because it was the 606th compound synthesized for testing. Salvarsan was the first organic anti-syphillitic, and a great improvement over the inorganic mercury compounds that had been used previously. A more soluble (but slightly less effective) arsenical compound, Neosalvarsan, (neoarsphenamine), became available in 1912. These arsenical compounds came with considerable risk of side effects, and they were supplanted as treatments for syphilis in the 1940s by penicillin.
The bacterium that causes syphilis is a spirochete, Treponema pallidum. Arsphenamine is not toxic to spirochetes until it has been converted to an active form by the body, so the discovery of this drug could not have been made without Hata's animal testing.
After leaving Erlich's laboratory, Hata continued parallel investigation of the new medicine in Japan.[2]
Structure
The structure was believed to feature an As=As bond, however, in 2005, it was shown to be a mixture of the cyclic trimer and a pentamer.[3][4][1] The revised structure features As-As single bonds, not double bonds.
References
- ↑ 1.0 1.1 "Chemical & Engineering News: Top Pharmaceuticals: Salvarsan". Retrieved 2007-08-25.
- ↑ Izumi, Yoshio; and Isozumi, Kazuo. (2001). Modern Japanese medical history and the European influence. Keio Journal of Medicine 50 (2), 91-99. PMID 11450598.
- ↑ "accsnet.ne.jp". Retrieved 2007-08-25.
- ↑ Lloyd NC, Morgan HW, Nicholson BK, Ronimus RS (2005). "The composition of Ehrlich's salvarsan: resolution of a century-old debate". Angew. Chem. Int. Ed. Engl. 44 (6): 941–4. doi:10.1002/anie.200461471. PMID 15624113.